透景生命：投资6800万元参股惠和生物 其已完成CC312管线的早期临床研究

Core Viewpoint - The investment by the company in Huihe Biotechnology is a strategic move to enhance its presence in the autoimmune disease sector, aligning with its long-term strategy of a comprehensive "diagnosis-treatment-monitoring" approach [1] Investment Details - The company has invested 68 million yuan to acquire a 9.2141% stake in Huihe Biotechnology, which has increased its registered capital by 175,992 yuan [1] - This investment is part of the company's strategy to establish a full-chain layout in the autoimmune disease field [1] Clinical Pipeline - Huihe Biotechnology's main pipeline, CC312, is currently in Phase I clinical trials, which carries the risk of not meeting clinical efficacy expectations [1] - The CC312 pipeline targets systemic lupus erythematosus (SLE) and other autoimmune diseases, addressing significant unmet clinical needs and demonstrating promising research potential [1] - Early clinical studies for the CC312 pipeline have been completed [1]